别名 Alpha-ENaC、Alpha-NaCH、Amiloride-sensitive sodium channel subunit alpha + [9] |
简介 This is one of the three pore-forming subunits of the heterotrimeric epithelial sodium channel (ENaC), a critical regulator of sodium balance and fluid homeostasis (PubMed:30251954, PubMed:32729833, PubMed:8023962, PubMed:8278374, PubMed:9792722). ENaC operates in epithelial tissues, where it mediates the electrodiffusion of sodium ions from extracellular fluid through the apical membrane of cells, with water following osmotically (PubMed:24124190, PubMed:28710092, PubMed:8278374). It plays a key role in maintaining sodium homeostasis through electrogenic sodium reabsorption in the kidneys (PubMed:12107247). Additionally, ENaC is essential for airway surface liquid homeostasis, which is crucial for proper mucus clearance (PubMed:24124190, PubMed:28710092).
Not functional. |
靶点 |
作用机制 ENaCα抑制剂 |
在研机构 |
原研机构 |
非在研适应症- |
最高研发阶段批准上市 |
首次获批国家/地区 美国 |
首次获批日期1981-10-05 |
靶点 |
作用机制 ENaCα抑制剂 |
非在研适应症- |
最高研发阶段临床阶段不明 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
作用机制 ENaCα抑制剂 [+2] |
在研适应症 |
非在研适应症 |
最高研发阶段临床前 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
开始日期2025-04-15 |
申办/合作机构 |
开始日期2024-10-10 |
申办/合作机构 |
开始日期2023-08-10 |
申办/合作机构 ![]() [+1] |